Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics

Izabela Lepiarz-Raba1, Ismail Gbadamosi2, Roberta Florea3

  • 1Laboratory for Translational Research in Neuropsychiatric Disorders (TREND), BRAINCITY: Center of Excellence for Neural Plasticity and Brain Disorders, Nencki Institute of Experimental Biology, Warsaw, Poland. i.lepiarz-raba@nencki.edu.pl.

PubMed

Insights

Metabolic interventions can enhance microglial phagocytosis of amyloid beta in Alzheimer's disease (AD). This review explores how modulating brain immune cell metabolism offers therapeutic potential for AD and other neurodegenerative diseases.

Area of Science:

  • Neuroimmunology
  • Neurodegenerative Diseases
  • Metabolic Pathways

Background:

  • Microglia, the brain's immune cells, play crucial roles in central nervous system health and disease.
  • Microglial functions, including phagocytosis and inflammatory responses, are intrinsically linked to their metabolic state.
  • Metabolic dysregulation is observed in Alzheimer's disease (AD), impacting microglial activity.

Purpose of the Study:

  • To review the scientific literature on microglial metabolism and its influence on microglial functions.
  • To synthesize the hypothesis that metabolic interventions can enhance microglial phagocytosis of amyloid beta (Aβ) in AD.
  • To explore the therapeutic potential of modulating microglial metabolism for AD treatment.

Main Methods:

  • Review of existing scientific literature on microglial metabolism and AD.
  • Analysis of the effects of various metabolites (glucose, lipids, ketone bodies, etc.) on microglial properties.
  • Examination of in vivo studies involving metabolic manipulation of microglial functions in AD models.

Main Results:

  • Microglial functions are closely tied to their metabolic state, offering targets for intervention.
  • Evidence suggests dysregulation of microglial metabolism in AD pathology.
  • Metabolic manipulation studies show potential for enhancing microglial phagocytosis of Aβ.

Conclusions:

  • Targeting microglial metabolism presents a promising therapeutic strategy for AD.
  • Further research is needed to address challenges before clinical application for clearing pathological protein deposits.
  • Understanding metabolic factors is key to harnessing microglia for neurodegenerative disease treatment.